Welcome to our dedicated page for Vicarious Surgical SEC filings (Ticker: RBOT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vicarious Surgical Inc. (RBOT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a public surgical robotics and medical device developer. These filings offer detailed information on the Vicarious Surgical System, the company’s operating expenses, capital structure, governance and listing status.
Through annual reports on Form 10-K and quarterly reports on Form 10-Q, Vicarious Surgical presents audited and interim financial statements, segment information for research and development, sales and marketing, and general and administrative activities, along with risk factors and management’s discussion of its development-stage business. Current reports on Form 8-K disclose material events such as registered direct offerings and private placements of common stock and warrants, at-the-market offering agreements, cash burn guidance, board and committee changes, and special meetings of stockholders to approve warrant exercises under New York Stock Exchange rules.
Filings also document listing and registration matters. For example, a Form 25 filed by the New York Stock Exchange relates to the removal from listing and registration of Vicarious Surgical’s publicly traded warrants, while separate 8-K items describe the NYSE’s notice to commence delisting proceedings for those warrants and the continued listing of the company’s Class A common stock under the symbol RBOT, subject to compliance with NYSE standards.
On Stock Titan, these documents are supplemented by AI-powered summaries that explain the key points of lengthy filings, such as complex financing terms, warrant structures, or at-the-market programs. Users can quickly see highlights from 10-K and 10-Q reports, understand the implications of Form 8-K events, and review proxy materials like definitive proxy statements (DEF 14A) that cover special meetings and stockholder proposals. The page also links to information about warrants, capital raises and other securities-related disclosures, helping investors and researchers analyze how Vicarious Surgical funds and governs the development of its single-port robotic surgery platform.
Vicarious Surgical Inc. (RBOT) filed a Form D reporting a private placement under Rule 506(b)Total Amount Sold of $11,730,000 and Total Remaining $0. The filing notes the total offering amount reflects gross proceeds assuming cash exercise of all warrants issued in the private placement.
The securities include equity, warrants or other rights to acquire securities, and securities to be acquired upon exercise. The Date of First Sale was 2025-10-09. Lake Street Capital Markets, LLC acted as placement agent, receiving a 6.0% cash fee on gross proceeds plus $100,000 expense reimbursement.
The company indicates proceeds are for working capital; while none are specifically set aside for officers or directors, some working capital may indirectly cover executive salaries and director stipends. Industry is listed as Health Care — Biotechnology, and issuer size was marked “Decline to Disclose.”
Vicarious Surgical Inc. entered into a securities purchase agreement for a capital raise using a registered direct offering and a concurrent private placement. The company will sell 588,300 shares of Class A common stock and pre-funded warrants to purchase up to 561,700 additional shares, together with Series A and Series B common warrants to purchase a total of 2,300,000 shares, all at an exercise price of
The pre-funded warrants are immediately exercisable at
Vicarious Surgical Inc. is offering Class A common stock at
Reported per-share net tangible book value before the offering is
Risk disclosures highlight barriers in the surgical robotics market: legacy systems have limited capabilities, are difficult to use, show low utilization, and carry significant capital investment costs—estimated up to
Vicarious Surgical Inc. (RBOT) director Joseph Edward Doherty was granted a stock option on 06/27/2025 to buy 8,003 shares of Class A common stock at an exercise price of $7.61 per share. After the grant, the reporting person beneficially owns 8,003 shares tied to this option on a direct basis.
The option's underlying shares will vest on 06/27/2026 or one day prior to the issuer's next annual meeting of shareholders, whichever is earlier, subject to the reporting person's continued service. The Form 4 was signed by an attorney-in-fact on 10/02/2025.
Vicarious Surgical Inc. (RBOT) Form 3 filed for Joseph Edward Doherty dated 06/27/2025 lists his relationship to the issuer as a Director and states that no securities are beneficially owned by the reporting person. The filing includes a Power of Attorney (Exhibit 24.1) and is signed by an attorney-in-fact on 10/02/2025. This is an initial Section 16 filing that records ownership status rather than a transaction.
Vicarious Surgical Inc. reported a leadership change on its board of directors. On September 25, 2025, the board appointed Joseph Doherty to serve as Chairman of the Board. He joined the board earlier in the year following his election at the annual meeting of stockholders held on June 27, 2025.
Doherty already serves as a member of the board’s Compensation Committee and as Chairman of the Nominating and Corporate Governance Committee, indicating an active role in executive pay decisions and board oversight. The company also issued a press release announcing his appointment, which is furnished as an exhibit but is not considered filed for liability purposes under securities laws.
Vicarious Surgical, Inc. filed a Form 8-K reporting a material event that attaches an Investor Presentation as Exhibit 99.1 and includes the interactive cover page XBRL file. The filing lists trading symbols for the company’s common stock and warrants on the New York Stock Exchange, including warrants to purchase one share of Class A common stock at an exercise price of
Vicarious Surgical Inc. (RBOT) filing a Form 144 notifies proposed sale of 40,427 shares of Class A common stock through two brokers for planned sale on 09/22/2025. The shares break down as 32,469 with Interactive Brokers (aggregate market value $189,943.65) and 7,958 with UBS Financial Services (aggregate market value $46,554.30), against 5,298,253 shares outstanding. The reporting person acquired a total of 45,339 shares over multiple dates via distributions and vesting from 2021–2024. In the prior three months the filer sold 4,912 shares for gross proceeds of $31,540.00. The signer certifies no undisclosed material adverse information.
Vicarious Surgical Inc. filed an 8-K reporting a material event dated
Vicarious Surgical Inc. filed a current report to let investors know it has updated its investor presentation as of September 8, 2025. Senior management plans to use this updated presentation in meetings with investors and analysts, including at the H.C. Wainwright 27th Annual Global Investment Conference in New York, where Chief Executive Officer Stephen From is scheduled to present at approximately 9:00 a.m. Eastern Time on September 10, 2025.
The updated investor presentation is available on the company’s investor relations website and is also furnished as Exhibit 99.1 to this report. The company notes that the presentation is furnished, not filed, which means it is not subject to certain liability provisions of the Securities Exchange Act and is not automatically incorporated into other securities filings unless specifically referenced.
FAQ
What is the current stock price of Vicarious Surgical (RBOT)?
What is the market cap of Vicarious Surgical (RBOT)?
